Twinhale - In silico trials for respiratory drug delivery

Are you developing an inhaled drug?

Do you face the challenge of a virtually unlimited number of inhalation devices and parameters?

The performance of your device in combination with your drug plays a crucial role in the success of clinical trials. Relying solely on in-vitro aerosol laboratory experiments to predict this success carries substantial risks.

Different deposition patterns resulting from different nebulizers simulated with Twinhale, our high-fidelity in silico model

Are you uncertain about which inhalation device and dosage will optimize the success of your clinical trial?

Leverage digital evidence from Twinhale - the world's best in silico model for pulmonary drug delivery

Schedule meeting now

In silico trials with Twinhale

Harness the advantage of in silico evidence

Using Twinhale, developers can assemble virtual patient cohorts tailored to a specific drug, device, or indication. In silico inhalation simulations are then performed across these cohorts to systematically evaluate how design choices - such as device configuration, operating parameters, formulation, and dosing - affect regional drug deposition.

This approach transforms an effectively unlimited design space into a small number of well-characterized, data-driven options. Twinhale provides quantitative evidence on where an inhaled drug is delivered in the lung and under which conditions, enabling informed optimization of locally delivered dose.

By accounting for patient variability and process uncertainty before entering the clinic, Twinhale helps de-risk development decisions, refine trial design, and improve confidence in downstream clinical outcomes.

Conducting a Twinhale-powered in silico trial is simple

Meeting

Schedule a 1h meeting where we identify your requirements. We will then design the in silico trial and select a suitable digital cohort.

Review

After you receive and reviewed our proposal for your customized in silico trial, we will run the in silico trial and analyze the results.

Results

Receive your results within 2 weeks providing you with quantitative and actionable insights.

Patient-specific lung geometries forming the basis of our digital twins. Find out more about how we generate in silico evidence using Twinhale here.

“We chose Ebenbuild because of their strong scientific expertise, very innovative technology and highly motivated team”

Gabriele Matschiner, Senior Director Translational Respiratory, Pieris Pharmaceuticals

"Working with Ebenbuild allows us to simulate drug deposition in diseased human lungs without performing extensive clinical studies."

Vanessa Neiens, Biology Lead, Pieris Pharmaceuticals

Benefits of our solution

Get your product to market in record time by harnessing the power of next generation in silico technology

Make crucial design or supplier decsions with confidence and peace of mind.

Our collaboration is key to unlocking the potential of the digital age in drug development, enhancing the health and well-being of millions of people. They count on us.

Not exactly what you're looking for? Our Twinhale software can do a lot more.

Some Twinhale customer projects we can talk about